In this week’s episode of The Spotlight Roundup, we check in with Fireside Project, the first-ever 24/7 psychedelic peer support line; the State of Oregon forms an advisory board to oversee the implementation of psilocybin use in specialized clinics; and The American Journal of Psychiatry publishes new guidance on how to safety and effectively use Ketamine and Esketamine.
Similar Posts
MindMed Financial Results & Business Update Q2 2021 ( Where Does MNMD/MMED Go From Here?)
MindMed’s Financial Results & Business Update for Q2 2021 are out!
In this episode, we’ll discuss MindMed, ( MMED: NEO), (MNMD: NASDAQ), (MMQ: FRA), who recently announced their Q2 financials and gave a business update.
This was an important, transitional quarter for the company for several reasons.
First, and perhaps most significantly, during Q2, co-founder JR Rahn stepped down as CEO, being replaced by Robert Barrow, who was previously Chief Development Officer.
Second, in terms of progress in the mission to heal mental health, MindMed made several strides in this quarter, which we’ll discuss today.
Pertinent links:
MindMed’s CEO Jr Rahn Steps Down:
https://thepsychedelicinvestor.com/2021/06/09/mindmed-announces-chief-executive-officer-transition/
Project Angie Update:
https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/
MindMed’s Collaboration with NextStage Therapeutics:
https://mindmed.co/news/press-release/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/
MindMed’s Pharmacogenetic Study:
https://thepsychedelicinvestor.com/2021/05/26/mindmed-and-liechti-lab-in-basel-switzerland-publish-first-pharmacogenetic-data-on-lsd-to-help-guide-personalized-dosing/
MMED’s Q2 Financial Results & Business Update:
https://thepsychedelicinvestor.com/2021/08/13/mindmed-announces-2021-q2-financial-results-cash-balance-of-157-usd-million-195-cad-million-to-execute-on-diverse-clinical-pipeline/
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedStock #MNMD
Interview With Sacha Hebbert
Mind Cure Health’s Senior Product and Marketing Manager, Sacha Hebbert, talks about the company’s recent launch of its product sales division.
Interview With Joshua White
Fireside Project’s Co-Founder and Director, Joshua White, speaks about the creation and the future of the organization.
The Top 5 Psychedelics Podcasts
New psychedelic podcasts are popping up every week, but which ones are worth listening to? Here’s a few of our favorites.
Transforming Your Life After 50 Through Microdosing with Cesar Marin
In this episode, we dive into the transformational testimonial of Cesar Maren’s experience with microdosing. Once a CNN TV producer, and now a full time advocate for the power of intentional microdosing, Cesar shares with us his journey how it helped transform his life.
How Do our Genes Affect an LSD TRIP?? New MindMed Study [ MMED / MNMD ]
Does our Genetic makeup influence our LSD trip?
Hey psychedelic Investors! MindMed ( MMED/MNMD/MMQ ) recently published a study in Nature Scientific Reports examining the different variations in our genes and how they affect one’s experience during an LSD trip.
The results are leading us to infer that, soon, we might be able to predict the strength, duration and perhaps even the subjective experience one undergoes when taking LSD based on certain genes that we possesses.
If we’re able to do that, how will this affect LSD’s medical uses in therapy setting?
Can we use this knowledge to move towards personalized dosing, where each individual will receive a different dose level for the same procedure, based on what their genetic code tells the therapist?
We will answer these questions in today’s episode .
We will also take a deep dive into the LSD study itself and explain why the findings are important for the future of psychedelic-assisted psychotherapy.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNews #MindMedstock